PRESS RELEASE published on 12/17/2024 at 22:15, 1 year 1 month ago NANOBIOTIX to Introduce Vision for Transforming Drug Design and Development with Next Nanotherapeutic Platform on 19 December 2024 Nanobiotix announces virtual event 'Accelerating the Future of Nanotherapeutics' on December 19, 2024, showcasing Curadigm Nanoprimer Platform for drug development Virtual Event NANOBIOTIX Curadigm Nanotherapeutics Nanoprimer
BRIEF published on 12/09/2024 at 22:20, 1 year 1 month ago Nanobiotix successfully completes phase 1 study in pancreatic cancer FDA Pancreatic Cancer Chemotherapy Phase 1 Study Radiotherapy
PRESS RELEASE published on 12/09/2024 at 22:15, 1 year 1 month ago NANOBIOTIX Announces Completion of Phase 1 Study of NBTXR3 (JNJ-1900) in Pancreatic Cancer Nanobiotix completes Phase 1 study of NBTXR3 in pancreatic cancer, showing promising outcomes & safety profile. FDA approves new trial. Full data to be shared in 2025 FDA Approval Pancreatic Cancer NANOBIOTIX NBTXR3 Phase 1 Study
BRIEF published on 11/25/2024 at 09:53, 1 year 2 months ago Threshold Crossing by Baillie Gifford at Nanobiotix Voting Rights Capital Threshold Crossing NANOBIOTIX Baillie Gifford
BRIEF published on 10/31/2024 at 08:35, 1 year 2 months ago NANOBIOTIX to Participate in Investor Conferences in November Innovation Investors Healthcare Conférences NANOBIOTIX
PRESS RELEASE published on 10/31/2024 at 08:30, 1 year 2 months ago NANOBIOTIX to Participate in Multiple Investor Conferences in November Nanobiotix to participate in multiple investor conferences in November, including Guggenheim, Stifel, and Jefferies events to discuss innovative healthcare approaches Investor Conferences Healthcare Innovation NANOBIOTIX Nanoparticle-based Approaches Late-stage Biotechnology
BRIEF published on 10/11/2024 at 22:20, 1 year 3 months ago Voting Rights and Share Capital Update by Nanobiotix Euronext Paris Voting Rights Nasdaq Shares Capital NANOBIOTIX
PRESS RELEASE published on 10/11/2024 at 22:15, 1 year 3 months ago Voting Rights and Shares Capital of the Company Nanobiotix discloses voting rights and shares capital information. Find out more about the company's innovative therapeutic approaches Voting Rights Biotechnology Shares Capital NANOBIOTIX Therapeutic Approaches
BRIEF published on 09/18/2024 at 22:20, 1 year 4 months ago NANOBIOTIX Provides Business Update and Reports Half Year 2024 Financial Results Revenue Increase Clinical Milestones Nanobiotix Financials NBTXR3 Progress Cash And Runway
PRESS RELEASE published on 09/18/2024 at 22:15, 1 year 4 months ago NANOBIOTIX Provides Business Update and Reports Half Year 2024 Financial Results Nanobiotix updates on operational progress and reports Half Year 2024 financial results, showcasing clinical milestones and licensing agreements with Janssen. Cash reserves extended until Q4 2025 Financial Results Clinical Milestones NANOBIOTIX Half Year 2024 Janssen Agreement
Published on 01/30/2026 at 14:00, 5 hours 20 minutes ago CCL to Hold Live Webcast to Discuss Fourth Quarter and Year End 2025 Results, Thursday, February 26, 2026, at 7:30 a.m. ET
Published on 01/30/2026 at 08:35, 10 hours 45 minutes ago Alaska Energy Metals Announces Closing Of Life Offering of Units
Published on 01/30/2026 at 08:00, 11 hours 20 minutes ago Troubadour Resources Intercepts Target Mineralization Near Surface during Phase 1 of the Multi-Phase Drill Program at Senneville Gold-Silver-Copper Property
Published on 01/30/2026 at 02:15, 17 hours 5 minutes ago Canex Metals Announces Success of Gold Basin Take-Over Bid, Extension of the Partial Revocation of the Cease-Trade Order Imposed on Gold Basin, Waiver of All Remaining Conditions, Initiation of the Share Take Up Process, and Mandatory 10-Day Extension
Published on 01/30/2026 at 00:00, 19 hours 20 minutes ago LIR Life Sciences Reports Positive Interim Preclinical Results from Comparative Animal Study of Novel CPP-Enabled Transdermal Delivery of GLP/GIP-Based Therapies
Published on 01/30/2026 at 18:31, 48 minutes ago Fuller, Smith & Turner PLC: Transaction in own shares
Published on 01/30/2026 at 17:45, 1 hour 35 minutes ago Schneider Electric launches a capital increase reserved for employees
Published on 01/29/2026 at 18:00, 1 day 1 hour ago GUILLEMOT CORPORATION: FULL-YEAR 2025 CONSOLIDATED TURNOVER UP 2%
Published on 01/29/2026 at 17:45, 1 day 1 hour ago LANSON-BCC ANNOUNCES 2025 REVENUES AND FINALISES THE ACQUISITION OF HEIDSIECK & C° MONOPOLE
Published on 01/29/2026 at 17:45, 1 day 1 hour ago Cegedim generated LFL revenue growth of 1.1% in 2025
